Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Diaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG
The name reflects a GLP-1-inspired mechanism in a dietary supplement, designed to support normal appetite signals and metabolism rather than to act as a pharmaceutical treatment
See if B12/MIC Injections are right for you
Tirzepatide's dual-agonist mechanism provides superior glycemic control with HbA1c reductions of 1.5-2.4%, compared to 1.2-1.8% for single-agonist alternatives
This is particularly true for low-income residents , where prevention potential is high
doi: 10.1371/journal.pone.0125361 244